Lucy Fraiser, Ph.D., a board-certified toxicologist, recently responded in a letter to the editor of Modern Healthcare about the publication’s recent coverage of the EPA’s work on ethylene oxide.
AdvaMed submitted comments to CMS on the CY 2023 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule.
AdvaMed submitted comments to CMS on the Calendar Year 2023 Physician Fee Schedule (PFS) proposed rule.
AdvaMed submitted a letter to CMS’s RFI on Medicare regarding ways to strengthen the Medicare Advantage program to align with the Vision for Medicare and CMS’ Strategic Pillars.
AdvaMed submitted comments to CMS the CY 2023 End Stage Renal Disease (ESRD) Prospective Payment System.
AdvaMed submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.
AdvaMed submitted comments to CMS on the Fiscal Year 2023 Hospital Inpatient Prospective Payment System proposed rule.
AdvaMed submitted comments to the Center for Medicare and Medicaid Services (CMS) on its Radiation Oncology (RO) Model proposed rule proposing to indefinitely delay the start date of the RO…
AdvaMed submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”
AdvaMed urged CDC to recognize the critical role evidence-based and FDA-approved/cleared devices can and should play in improving pain management and reducing opioid-related harms.